These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23567227)

  • 1. [Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
    Sibaud V; Robert C
    Ann Dermatol Venereol; 2013 Apr; 140(4):266-73. PubMed ID: 23567227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dermatologic side effects induced by new angiogenesis inhibitors].
    Sibaud V; Garrido-Stowhas I; Cottura E; Chevreau C
    Bull Cancer; 2011 Oct; 98(10):1221-9. PubMed ID: 22001771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapeutic agents and the skin: An update.
    Heidary N; Naik H; Burgin S
    J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Deslandres M; Sibaud V; Chevreau C; Delord JP
    Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel molecular targeted therapies for refractory thyroid cancer.
    Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
    Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
    Bretagne M; Boudou-Rouquette P; Huillard O; Thomas-Schoemann A; Chahwakilian A; Orvoen G; Arrondeau J; Tlemsani C; Cessot A; Cabanes L; Blanchet B; Coriat R; Alexandre J; Goldwasser F
    Bull Cancer; 2016 Mar; 103(3):259-72. PubMed ID: 26832420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    Montemurro M; Gelderblom H; Bitz U; Schütte J; Blay JY; Joensuu H; Trent J; Bauer S; Rutkowski P; Duffaud F; Pink D
    Eur J Cancer; 2013 Mar; 49(5):1027-31. PubMed ID: 23140824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for therapeutic drug monitoring of targeted anticancer therapies.
    Gao B; Yeap S; Clements A; Balakrishnar B; Wong M; Gurney H
    J Clin Oncol; 2012 Nov; 30(32):4017-25. PubMed ID: 22927532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Petrelli A; Giordano S
    Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to manage hypersensitivity reactions to biological agents?
    Barbaud A; Granel F; Waton J; Poreaux C
    Eur J Dermatol; 2011; 21(5):667-74. PubMed ID: 21742594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
    Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
    Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Indications and current development of new targeted therapies in pediatric oncology].
    Leblond P; Geoerger B
    Bull Cancer; 2011 May; 98(5):527-39. PubMed ID: 21596652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cutaneous side effects of sorafenib and sunitinib].
    Autier J; Mateus C; Wechsler J; Spatz A; Robert C
    Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
    [No Abstract]   [Full Text] [Related]  

  • 16. Current and future management of GIST.
    Blanke C
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):582-3. PubMed ID: 17099615
    [No Abstract]   [Full Text] [Related]  

  • 17. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
    Andriamanana I; Gana I; Duretz B; Hulin A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():83-91. PubMed ID: 23562906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
    Massey PR; Okman JS; Wilkerson J; Cowen EW
    Support Care Cancer; 2015 Jun; 23(6):1827-35. PubMed ID: 25471178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S23-30. PubMed ID: 17239287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.